Answers are grounded in this paper and cite their sources.
Current radiotherapy (RT) treatment strategies are developed based on decades-old radiobiological modeling, preclinical work, and population-driven trials. The pre-determined total dose is divided into smaller dose fractions and delivered over several weeks. The treatment responses are typically assessed months after the treatment. However, due to the presence of heterogeneity, the conventional one-dose-fits-all strategy may pose a challenge to optimising outcome. A personalized regimen based on individual response will be favoured. As an alternative strategy, we are proposing a small-data AI-derived phenotypic medicine (PM) platform that does not to any model training and testing in guiding clinicians to dose patient based on individual treatment response in real-time with their own data. It potentially reduces unnecessary toxicity for good responders and prevents inadequate disease control for poor responders.
No takes yet. Share an insight, caveat, or question.
Ming et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: